ASH 2016 | CPX-351 liposome injection vs standard cytarabine and daunorubicin for older high-risk AML patients

Jeffrey Lancet

Press brief presented by Jeffrey E. Lancet, MD of Moffitt Cancer Centre, Tampa, FL, on ‘Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubicin: subgroup analysis of a large Phase III trial’. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video  
Similar topics